二甲双胍使用与老年2型糖尿病患者认知下降减缓及痴呆风险降低相关:悉尼记忆与衰老研究
该前瞻性观察研究纳入1037名70-90岁无痴呆社区老年人,随访6年,其中123例糖尿病(67例使用二甲双胍)。结果显示,使用二甲双胍的糖尿病患者整体认知和执行功能下降显著慢于未使用者,且未使用二甲双胍者发生痴呆的风险显著更高(OR 5.29,95%CI 1.17-23.88,P=0.05)。
要点
- 使用二甲双胍的老年糖尿病患者认知下降速度显著慢于未使用者。
- 未使用二甲双胍的糖尿病患者痴呆风险显著高于使用二甲双胍者(OR 5.29)。
- 需大规模随机研究确认二甲双胍与认知获益的因果关系。
核心结论
- 老年2型糖尿病患者使用二甲双胍与较慢的认知下降和较低的痴呆风险相关。
研究设计与样本
- 前瞻性观察研究纳入1037名70-90岁无痴呆社区老年人,其中123例糖尿病(67例使用二甲双胍)。
- 每2年进行神经心理测试评估认知功能,痴呆由多学科小组判定。
- 基线及2年时对526名参与者进行MRI测量全脑、海马及海马旁体积。
主要发现
- 使用二甲双胍的糖尿病患者整体认知和执行功能下降显著慢于未使用二甲双胍者。
- 未使用二甲双胍的糖尿病患者痴呆发生率显著高于使用二甲双胍者(OR 5.29,95%CI 1.17-23.88,P=0.05)。
临床怎么用
- 对于老年2型糖尿病患者,二甲双胍的使用可能与认知功能保护相关,但需结合个体情况权衡。
局限性
- 为观察性研究,无法确定因果关系。
- 二甲双胍组样本量较小(67例),痴呆事件数有限。
- 需大规模随机对照研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes (diabetes) is characterized by accelerated cognitive decline and higher dementia risk. Controversy exists regarding the impact of metformin, which is associated with both increased and decreased dementia rates. The objective of this study was to determine the association of metformin use with incident dementia and cognitive decline over 6 years in participants with diabetes compared with those not receiving metformin and those without diabetes. RESEARCH DESIGN AND METHODS: A prospective observational study was conducted of N = 1,037 community-dwelling older participants without dementia aged 70-90 years at baseline (the Sydney Memory and Ageing Study). Exclusion criteria were dementia, major neurological or psychiatric disease, or progressive malignancy. Neuropsychological testing measured cognitive function every 2 years; a battery of tests measured executive function, memory, attention/speed, language, and visuospatial function individually. These were used to determine the measure of global cognition. Incident dementia was ascertained by a multidisciplinary panel. Total brain, hippocampal, and parahippocampal volumes were measured by MRI at baseline and 2 years (n = 526). Data were analyzed by linear mixed modeling, including the covariates of age, sex, education, BMI, heart disease, hypertension, stroke, smoking, and apolipoprotein Eε4 carriage. RESULTS: Of n = 1,037, 123 had diabetes; 67 received metformin (DM+MF) and were demographically similar to those who did not (DM-noMF) and participants without diabetes (no-DM). DM+MF had significantly slower global cognition and executive function decline compared with DM-noMF. Incident dementia was significantly higher in DM-noMF compared with DM+MF (odds ratio 5.29 [95% CI 1.17-23.88]; P = 0.05). CONCLUSIONS: Older people with diabetes receiving metformin have slower cognitive decline and lower dementia risk. Large randomized studies in people with and without diabetes will determine whether these associations can be attributed to metformin.
引用
- Samaras K, Makkar S, Crawford JD, et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care. 2020. PMID: 32967921. doi:10.2337/dc20-0892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。